Mi D - Search Results

1

Small-molecule Modulators Targeting SHP2 for Cancer Therapy.

Mi D, Li Y, Chen Y. Mi D, et al. Anticancer Agents Med Chem. 2023;23(5):498-504. doi: 10.2174/1871520622666220921093052. Anticancer Agents Med Chem. 2023. PMID: 36154594 Review.

2

Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin.

Li Y, He Y, Shao T, Pei H, Guo W, Mi D, Krimm I, Zhang Y, Wang P, Wang X, Liu M, Yi Z, Chen Y. Li Y, et al. Among authors: mi d. J Med Chem. 2019 May 23;62(10):4949-4966. doi: 10.1021/acs.jmedchem.9b00059. Epub 2019 May 8. J Med Chem. 2019. PMID: 31026162

3

In vivo target protein degradation induced by PROTACs based on E3 ligase DCAF15.

Li L, Mi D, Pei H, Duan Q, Wang X, Zhou W, Jin J, Li D, Liu M, Chen Y. Li L, et al. Among authors: mi d. Signal Transduct Target Ther. 2020 Jul 27;5(1):129. doi: 10.1038/s41392-020-00245-0. Signal Transduct Target Ther. 2020. PMID: 32713946 Free PMC article. No abstract available.

4

An instructive attempt on developing aptamer-constructed PROTAC for breast cancer treatment.

Zhang Y, Mi D, Chen Y. Zhang Y, et al. Among authors: mi d. Mol Ther Nucleic Acids. 2022 Nov 5;30:351-352. doi: 10.1016/j.omtn.2022.10.008. eCollection 2022 Dec 13. Mol Ther Nucleic Acids. 2022. PMID: 36381581 Free PMC article. No abstract available.

5

B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.

Gu H, He J, Li Y, Mi D, Guan T, Guo W, Liu B, Chen Y. Gu H, et al. Among authors: mi d. J Med Chem. 2022 Dec 8;65(23):15559-15583. doi: 10.1021/acs.jmedchem.2c01433. Epub 2022 Nov 28. J Med Chem. 2022. PMID: 36441945 Review.

6

A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer.

Wang L, Mi D, Hu J, Liu W, Zhang Y, Wang C, Chen Y, Chen C. Wang L, et al. Among authors: mi d. Cancer Lett. 2023 Feb 28;555:216049. doi: 10.1016/j.canlet.2022.216049. Epub 2023 Jan 3. Cancer Lett. 2023. PMID: 36608865

7

Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway.

Zhang Y, Chen J, Mi D, Ling J, Li H, He P, Liu N, Chen Q, Chen Y, Huang L. Zhang Y, et al. Among authors: mi d. Cancer Lett. 2023 Apr 28;560:216142. doi: 10.1016/j.canlet.2023.216142. Epub 2023 Mar 23. Cancer Lett. 2023. PMID: 36965539

8

Corrigendum to "Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway" [Canc. Lett. (2023) 216142].

Zhang Y, Chen J, Mi D, Ling J, Li H, He P, Liu N, Chen Q, Chen Y, Huang L. Zhang Y, et al. Among authors: mi d. Cancer Lett. 2023 Jul 28;567:216195. doi: 10.1016/j.canlet.2023.216195. Epub 2023 May 6. Cancer Lett. 2023. PMID: 37156646 No abstract available.

9

Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design.

Mi D, Li Y, Gu H, Li Y, Chen Y. Mi D, et al. Eur J Med Chem. 2023 Aug 5;256:115444. doi: 10.1016/j.ejmech.2023.115444. Epub 2023 May 8. Eur J Med Chem. 2023. PMID: 37178483 Review.

10

Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer.

He J, Wang L, Mi D, Guan T, Liu W, He P, Gu H, Li Y, Peng Y, Jia AQ, Chen C, Chen Y. He J, et al. Among authors: mi d. J Med Chem. 2023 Jun 8;66(11):7421-7437. doi: 10.1021/acs.jmedchem.3c00090. Epub 2023 May 22. J Med Chem. 2023. PMID: 37212861

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

254 results

Search Page